Tag Archives: Advances In Cancer Treatment

Cancer Research, Immuno-Oncology, Immunotherapy for Cancer

Genetic Advances Made in Prostate Cancer Identification

Prostate cancer affects approximately 15 percent of males in their lifetime, and is second only to skin cancer. Recent identification of an overactive gene that accelerates prostate cancer could lead to development of a more effective treatment.

Prostate Cancer Evolves Beyond Drugs

Most prostate tumors are caused by a form of cancer called adenocarcinoma. In advanced stages, adenocarcinoma is treated with drugs that block androgens, the male hormones that fuel the tumor. Unfortunately, the tumors have evolved into a more aggressive, androgen-resistant form called neuroendocrine prostate cancer.

Prostate Cancer Identification
Prostate Cancer Identification

A cross-disciplinary team supported by the Prostate Cancer Foundation discovered a gene known as N-Myc that appears to be the driver behind the change to the more aggressive form. While N-Myc is not usually found in prostate cancer, it has been known to occur in other forms such as neuroblastoma, a rare cancer of the nervous system found in children.

A Pathway to New Treatment Methods

When N-Myc goes into overdrive, it teams up with a protein called EZH2 to block the tumor’s androgen signaling and “flips the switch” on the molecular program that leads to the more aggressive neuroendocrine form. Dr. Jonathan W. Simons, president and CEO of the Prostate Cancer Foundation, calls this a “game-changing” discovery that can enable development of more successful treatments.

Personalized, Non-Toxic Treatments for Prostate Cancer

Issels® offers a wide range of Immunotherapy for Cancer protocols, including vaccines and NK cells that have been used to treat patients with prostate cancer, melanoma, leukemia and all other forms. Contact us today to find out how Immunotherapy for Cancer at Issels® can help you or your loved one.

Alternative Cancer Treatment, Cancer Research, Uncategorized

Promising New Treatments Use Molecular Cancer Classifications for Melanoma

Cancer Treatment in Tijuana
Preventing Melanoma

In a groundbreaking effort that could lead to improved strategies even for stage four melanoma treatment, researchers have gathered national data to better determine cancer risk of four major molecular subtypes of cancer. What does this mean for your cancer treatment efforts? Issels® wants you to know.

Improved classification of data = better treatment.
Broken down by age, race/ethnicity, poverty level, and other factors, the data gathered will help researchers more accurately determine the degree of risk, and cancer patients better understand health implications based on their breast cancer subtype, as each of the four major molecular subtypes responds differently to treatment and has varying survival rates.

More access = better treatment.
Also improving strategies for stage four melanoma treatment, the data gathered has been recorded by cancer registries nationwide, making widely available medically important information to guide therapeutic strategies for these cancer subtypes.

Faster identification = better treatment.
The new diagnostic categories identified by researchers will further support the prevention and treatment of multiple types of cancer, as well as monitor their incidence and outcomes, providing further necessary data for the use in stage four melanoma treatment.

Promising findings = a better future for you.
The findings, as well as the statistical analysis of the most common types of cancer, were reported in “The Annual Report to the Nation on the Status of Cancer, 1975-2011,” which also confirmed encouraging trends in cancer mortality among men, women, and children alike, reflecting the progress made over the years in cancer prevention, early detection, and treatment.

Struggling with stage four melanoma treatment? Issels® help you on the path to recovery. Contact us today.